secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcellx, Inc. (ACLX)
CIK:        0001786205
Form:       8-K
Filed at:   2023-11-02T23:59:59+00:00
Accession:  0001193125-23-268942
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcellx reports 100% ORR, 76% CR rate in Phase 1 CART-ddBCMA trial; median follow-up 22 mo
--------------------------------------------------------------------------------

- Overall response rate 100% per IMWG criteria; 29/38 patients (76%) achieved CR or sCR.
- Median duration of response, PFS, and OS not reached at 22 months median follow-up.
- 6-, 12-, 18-month PFS rates by KM: 92%, 74%, 67%. Durable in high-risk subgroups.
- All 38 patients triple-refractory; 68% penta-refractory; 89% refractory to last line.
- CART-ddBCMA well tolerated; manageable CRS/ICANS, no delayed neurotoxicity or parkinsonism.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1786205/000119312523268942/0001193125-23-268942-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1786205/000119312523268942/d572316d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-268942

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer